



Optima IPL

Think Outside the Eye



Treat the root cause:
Chronic Inflammation

D|T|YOptical
flexible solutions you can trust
דטי שדרותי אופטיקה - 052-3270220 - 03-9341133 - www.dty.co.il

Lumenis®
Energy to Healthcare



Think Outside the Eye

Treat periocular inflammation

Do your patients suffer from dry, itchy, red or burning eyes?

Periocular inflammatory conditions, such as Rosacea and eyelid telangiectasia, affect millions of Americans every year. Rosacea and Telangiectasia can have a significant impact on quality of life with visible symptoms such as redness, swelling and irritation.

When the disease manifests in the periocular region, it may lead to ocular conditions. **Over 80% of Rosacea patients suffer from inflammatory ocular conditions, such as Meibomian Gland Dysfunction (MGD)**¹.

Optima IPL is a drug-free, drop-free solution that combines Intense Pulsed Light (IPL) and Lumenis unique Optimal Pulse Technology (OPT™) and is intended to treat ~20 different skin indications, including Rosacea and other skin inflammatory conditions.

“Although rosacea is predominantly a skin condition, it often leads to eyelid and ocular surface inflammation, which can then trigger Meibomian Gland Dysfunction (MGD)”²

(Ronald N. Gaster, MD)

First-of-its-kind, drug-free, drop-free, light-based treatment

Unlike conventional treatments, Optima IPL uses advanced technology to deliver a controlled amount of intense pulsed light around the eye.


With every pulse of light, this first-of-its-kind, energy-based therapy works to control the inflammatory process and to **stop the vicious cycle of inflammation - displacing the need for medications and providing long-lasting results.**

Treat the root cause: chronic inflammation


Inflammatory skin diseases are characterized by the formation of vascular abnormalities, which release inflammatory agents. When occurring in proximity to the eyes, these mediators propagate via the orbital vasculature to the eyelids, often resulting in inflammation of the eyelids, which, in turn, may trigger ocular complications^{2,6,7}.

Optima IPL energy is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombosis. A major source of inflammation threatening the eyelids is then removed.

Optima IPL alleviates abnormal blood vessels and reduces the level of pro-inflammatory mediators^{5,6} and Demodex mites⁷.



Optima IPL effectively reduces the inflammation




Less inflammatory markers in treated side, compared to untreated side³

Alleviates abnormal blood vessels and improves symptoms such as redness and itchiness



Baseline

Courtesy of Rob Noecker, MD



After 4 months




After 6 months



Before

Courtesy of Laura M. Periman, MD



After 2 IPL treatments

"Many of the patients who received Optima IPL treatment (for Rosacea) reported that not only the inflammation on their skin improved but so did their ocular symptoms effected by it."

Rolando Toyos, MD

Lumenis, the inventor of IPL, is proud to present Optimal Pulse Technology (OPT™)

Uniquely designed for the periocular region

Safety

Homogenous pulses


- No spikes in energy
- The energy you choose is the energy you get

Efficacy


Reproducible pulses

- Consistent level of energy between pulses

Other IPL systems



Lumenis IPL with OPT™



Patented water cooled tip for the safe and comfortable treatment of the periocular region

SapphireCool™ chiller tip allows to:

1. Reach higher levels of energy for achieve optimal results
2. While keeping the treatment safe and comfortable for the patient



Modular system that includes additional skin conditions and aesthetic treatments

- Optima IPL is a modular system, allowing to extend your practice to additional ~20 different skin indications aesthetic treatments
- ExpertFilters™ tailored to the skin type and condition for optimized results. All suitable for one handpiece



Technical Parameters of Optima IPL

System Specifications

Dimensions [without ResurFX]	44 x 51 x 47 cm (17 x 20 x 19 inches)
Dimensions [with ResurFX]	44 x 51 x 62 cm (17 X 20 X 24 inches)
Weight [without ResurFX]	40 kg / 88 lbs
Weight [with ResurFX]	55 kg / 121 lbs
Electrical requirements	100 – 240 VAC, 12A max., 50/60 Hz, single phase, dedicated line

Universal IPL

Spectrum	400-1200 nm
ExpertFilters	Acne (400 nm-600 nm & 800 nm-1200 nm); 515 nm; Vascular (530 nm-650 nm & 900 nm-1200 nm); 560 nm; 590 nm; 615 nm; 640 nm; 695 nm; 755 nm
Lightguides	15 x 35 mm; 8 x 15 mm, 6 mm Ø
Fluence	Up to 35 J/cm ² for rectangular lightguides; Up to 56 J/cm ² for the round lightguide
Pulse Duration	4-20 ms
Pulse Delay	5-150 ms
Pulse Characteristic	Multiple Sequential Pulsing
Repetition Rate	Up to 1 Hz
Cooling	Continuous contact cooling

Risks and warning (non-inclusive list):

Lumenis energy based treatments are not suitable for everyone and, like every treatment, can carry some risks. Treatment with M22 Optima IPL is contra-indicated for patients with the following conditions in the treatment area: active infections, dysplastic nevi, open lacerations, abrasions, and prolonged sun-exposure. Caution is advised for patients with photosensitivity, immune/coagulation/hormonal disorders, or a history of Herpes simplex at or near the treatment area. Side effects include (but are not limited to) discomfort, excessive edema/erythema, bruising, burns, scarring, and changes in pigmentation. Please refer to the operator manual for a complete list of intended uses, contraindications and risks.

1. Viso et al. (2014) Eur Ophthalmol Rev 8(1):13-6; 2. Gaster (2016), insert to Cataract & Refractive Surgery Today 2; 3. Liu et al. (2017) Am J Ophthalmol 183:81-90.; 4. Yin et al. (2018) Curr Eye Res 43(3):308-13; 5. Prieto et al. (2002) Lasers Surg Med 30(2):82-5; 6. Kassir et al. (2011) J Cosmet Laser Ther 13(5):216-22; 7. Papageorgiou et al. (2008) Br J Dermatol 159(3):628-32

 Lumenis Ltd.
Yokneam Industrial Park
Hakidma Street 6, P.O.B. # 240
Yokneam 2069204, ISRAEL
Tel +972 4 959 9000

 Lumenis (Germany) GmbH
Heinrich-Hertz-Str 3 D-63303
Dreieich-Dreieichenhain
GERMANY
Tel +49 (0) 6103 8335 0

AMERICAS
San Jose, CA, USA
Tel +1 408 764 3000
+1 877 586 3647
Fax +1 408 764 3999

JAPAN
Tokyo, Japan
Tel +81 3 4431 8300
Fax +81 3 4431 8301

ASIA / PACIFIC
Beijing, China
Tel +86 10 5737 6677
Gurgaon, India
Tel +91 124 422 07 95
Kowloon, Hong Kong
Tel +852 217 428 00
Fax +852 272 251 51

EMEA
Dreieich Dreieichenhain,
Germany
Tel +49 6103 8335 0
Fax +49 6103 8335 300
Roma (RM), Italy
Tel +39 06 90 75 230
Fax +39 06 90 75 269
Hertfordshire, UK
Tel +44 20 8736 4110
Fax +44 20 8736 4119

 **Lumenis®**
Energy to Healthcare



Rx ONLY



www.lumenis.com/Ophthalmology

The indications are only relevant where they were approved by the Regulatory Authorities. The Dry eye indication has not been cleared in the United States by the FDA.

© 2019 All Rights Reserved. The Lumenis Group of Companies. PB-2012273 Rev. A. Lumenis, its logo, M22, OPT, Multiple-Sequential Pulsing, ExpertFilters, SapphireCool lightguides, ResurFX and CoolScan are trademarks or registered trademarks of the Lumenis Group of Companies. Specifications are subject to change without notice Lumenis is ISO 13485:2012 certified. M22 is CE approved. | M22 is FDA cleared.